Clinical trial · no report yet · Phase 3
G-HOPE-001
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
- NCT06238843 ↗
- Active, not recruiting
- Innovent Biologics (Suzhou) Co. Ltd.
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 17 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）; IBI343
- Arms
- Active Comparator: control arm · Active comparator
- IBI343 monotherapy · Experimental
- Enrollment
- 464
- Primary outcomes
- progression free survival(PFS)
- overall survival(OS)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Start
- Jun 30, 2024
- Primary completion
- Dec 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06238843 · updated May 13, 2026